Bristol-Myers, Biocon sign option agreement for insulin drug
As part of the agreement, Biocon will conduct clinical studies to further characterize IN-105’s clinical profile till the completion of phase II while Bristol-Myers Squibb will have a
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
The package, which is manufactured by Keystone Folding Box Company, is used for prescription products, physician’s samples and clinical trial materials. According to Walmart, Ecoslide-RX offers large, easy-to-read
The companies signed a long-term supply agreement in September 2010 and worked towards completing validation and setting up a well characterised procedure. Fujifilm Diosynth Biotechnologies’ Billingham managing director